OOIR: Observatory of International Research

Papers

(The TQCC of Drug Metabolism and Pharmacokinetics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Refined CYP2E1∗ Template∗∗ system to decipher the ligand-interactions	179
Functional assessment of immortalized human brain microvascular endothelial cells with different passage numbers: A case study for a prospective proposal on variability management of in vitro blood-br	90
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity	55
Protection of mice against carbon tetrachloride-induced acute liver injury by endogenous and exogenous estrogens	47
CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children	23
Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model	21
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum	21
Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms	21
Functional characterization of human organic anion transporter 10 (OAT10/SLC22A13) as an orotate transporter	15
The refined CYP2B6-Template system for studies of its ligand metabolisms	14
Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development	13
Assessing victim drug-drug interaction – Reaction phenotyping of CYP and non-CYP	12
Drug induced organ toxicity: Transporter roles and derisking approaches	12
Potential ADME-related issues for PROTACs	12
Identification and characterization of novel metabolites of F2-isoprostanes	12
Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors	11
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy	11
Modern pediatric drug development: Practical case examples and regulatory outcomes from novel applications of modelling	11
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant	10
Establishment of the relay method for low-turnover compounds in hepatocyte	9
Prediction and validation of human hepatobiliary clearances and hepatic concentrations of transported drugs using the relative expression factor (REF) and PET imaging approaches	9
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib	9
The spectrum of hepatic clearance models, from old to new	9
Synthesis and characterization of human metabolites of the echinocandid drug rezafungin by microbial biotransformation	9
UGT-mediated clearance IVIVE may be improved using relative activity factor approach	8

A practical approach for measuring acyl glucuronide migration half life	8
Monocarboxylate transporter 10: substrate-dependent mode of transport	8
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model	8
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies	7
Metabolism of DHED in vitro and in vivo to support drug optimization	7
Can LS180 cells predict metabolism and drug-drug interaction potential of UGT2B17 substrates?	7
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption	7
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human	7
Dynamic free fraction: concept, methodology and impact on hepatic clearance prediction using the well-stirred model	7
Utilizing various plasma protein binding tools for free fraction determination of lipophilic and lipopeptide drugs	7
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics	6
Evaluation of a cost-effective in vitro human model for predicting intrinsic hepatocyte clearance of slowly metabolized compounds	6
Assessment of covalent binding body burden in Hmrel human hepatocyte co-culture model for metabollically low turnover compounds	6
Enriching metabolite fractions for assessment of AHR activation potential: a proof of concept study	6
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor	6
Plasma protein binding of oligonucleotides using rapid agarose gel electrophoretic mobility shift assay	6
Redox metabolism in intestine and liver aggravates retronecine-type pyrrolizidine alkaloids-induced liver injury	6
Validation of LC-MS/MS method for the quantification of buprenorphine and its metabolites in rat’s blood, oral fluid, salivary gland and application the assay on pharmacokinetic study	6
Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes	5
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis	5
A novel method for predicting the unbound valproic acid concentration	5
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics	5
Synthetic mRNA for ex vivo therapeutic applications	5
Adenosine deaminases acting on RNA modulate the expression of the human pregnane X receptor	5
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality	5
Feature importance of machine learning prediction models shows structurally active part and important physicochemical features in drug design	5
Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam	5
Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells	5
Understanding the role of CYP3A in the metabolism of kinase inhibitors marketed in the past decade to better manage the risk of clinical drug-drug interactions	5
Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders	5
Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human	5
Formation of reactive metabolites of benzbromarone in humanized-liver mice	5
Novel food drug interaction mechanism involving acyclovir, chitosan and endogenous mucus	5
Clinical studies on pharmacogenomics and DDIS involving drug transporters	5
Latest developments in nitrosamine structure-activity relationships for carcinogenicity	5
Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil	5
Relative expression versus activity factor (ref vs. raf) to estimate fractional contribution of individual UGT isoforms (FGLUC) in drug glucuronidation	4
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation	4
Human aldo-keto reductase (AKR) 1C1 and 1C2 act as coactivators of pregnane X receptor, a master regulator of drug-metabolizing and gluconeogenesis enzymes	4
Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model	4
Basic tenets for the ADME of protein therapeutics	4
Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolab	4
In vitro metabolism of the new antifungal dapaconazole using liver microsomes	4
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]	4
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	4
Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate	4
Effect of linker-payload design on the PK of ADCS	4
Applications of model simulation in pharmacological fields and the problems of theoretical reliability	4
Buffer compositions strongly impact the in vitro assessment of CYP fraction metabolized using human liver microsomes or expressed isoenzymes	4
Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs-	4

Story of maturation - Modelers vs models in the paediatric space	4
Enzyme induction fundamentals, assays, data interpretation and in vivo translation	4
One size does not fit all: Preclinical tools to characterize the pharmacokinetics and biodistribution of GaINAc-siRNA	3
Evaluation of biliary excretion process of drugs and bile acids using permeation assay by a novel in vitro hepatocyte culture system (ICHEP)	3
Hepatocyte formation, reactivity, and stability differences of acyl glucuronide and acyl coenzyme a conjugates	3
This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta	3
Opportunities and challenges in drug development for retinal diseases	3
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib	3
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions	3
From stratified dose adjustment to personalised dosing: Linking LCMS proteomics in tissues to more clinically practical liquid biopsy samples – Opportunities and challenges	3
Cannabinoid-induced drug-drug interactions with hydromorphone.	3
The characterization of the pharmacokinetic profile of anti-tumor B (ATB) in oral cancer patients	3
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates	3
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene	3
Pharmacokinetic interaction of caffeine and theophylline in mice	3
Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules	3
An approach using a gamma-distributed delay model to evaluate the anticancer effect of doxorubicin-encapsulated polymeric micelles by predictive pharmacokinetic-pharmacodynamic modeling	2
An overview of CDE technical guideline for nonclinical study of ADCS: importance and strategy of studying release of payload-containing components from ADC and their further metabolism	2
Title page	2
Gene and Oligonucleotide Delivery	2
Development of a fluorescent-labeled trapping reagent to evaluate the risk posed by acyl-CoA conjugates	2
In vivo and in vitro biotransformation of molnupiravir (MOV), An oral prodrug of the antiviral ribonucleoside analog Β-D-N4-hydroxycytidine (NHC)	2
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system	2
What is the role of CYP1A1 in drug metabolism?	2
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human	2
Exploring the human 3D small intestinal model (epiintestinaltm) for improved prediction of oral absorption, metabolism and complex drug-drug interactions of small molecule drugs	2
Novel approaches and troubleshooting for developing a high-throughput oligonucleotide LC-MS method beyond the current stage	2
Plasma protein binding in special populations: do current PBPK models correctly account for potential changes to fraction unbound?	2
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS	2
Prediction of human clearance using human liver microsomes and hepatocytes with 455 drugs	2
Strategies for enhancing oral exposure of water-insoluble compounds	2
Deciphering the cell and zonal distribution of drug metabolizing enzymes and transporters in humans by single cell transcriptomics	2
Novel multi-tissue chips for predictive pharmacokinetic studies	2
Physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product	2
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human	2
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges	2
Quantitation and characterization of glucosylsphingosine in cerebrospinal fluid (CSF), plasma, and brain of monkey model with Gaucher disease	2
Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance	2
Optimization of methods for reducing turnaround time and compound consumptionwith echo liquid handling and automation enabling high capacity analysis for ADME screening	2
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition	2
Using quantitative systems pharmacology (QSP) models to characterize the PK of novel drug modalities	2
Comparison of clearance and metabolic pathways in suspension hepatocytes and hepatopac cultures	2
Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers	1
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	1
Appreciation to Reviewers	1
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics	1
Constitutive androstane receptor-responsive elements for mouse Cyp1a2 transcriptional activation induced by constitutive androstane receptor ligands	1
Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation	1
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants	1
Characteristics of membrane transport, metabolism, and target protein binding of cyclic depsipeptide destruxin E in HeLa cells	1
Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity	1
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	1
Identification of miRNAs that regulate human CYP2B6 expression	1
Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice	1
Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice	1
Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modeling	1
Advanced in vitro evaluation of drug-induced kidney injury using microphysiological systems in drug discovery and development	1
In vitro uptake of an MC3 lipid nanoparticle formulation by mice, non-human primate, and human hepatocytes and Kupffer cells	1
A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study	1
Gene and oligonucleotide delivery via micro- and nanobubbles by ultrasound exposure	1
Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations	1
Functional role of serine 318 of the proton-coupled folate transporter in methotrexate transport	1
Systematic identification and characterization of cynomolgus macaque solute carrier transporters	1
Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries	1
Adenovirus vector-based vaccine for infectious diseases	1
Human brain organoids for understanding substance use disorders	1
Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings	1